1 – 10 of 19
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Recombinant α
1-Microglobulin (rA1M) Protects against Hematopoietic and Renal Toxicity, Alone and in Combination with Amino Acids, in a
177Lu-DOTATATE Mouse Radiation Model.
(
- Contribution to journal › Article
- 2021
-
Mark
Kidney protection with the radical scavenger α1-microglobulin (A1m) during peptide receptor radionuclide and radioligand therapy
(
- Contribution to journal › Article
-
Mark
177Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α1-Microglobulin (A1M), Including Kidney Damage Assessment Using 99mTc-MAG3 Imaging
(
- Contribution to journal › Article
- 2017
-
Mark
Combined Magnetomotive ultrasound, PET/CT, and MR imaging of (68)Ga-labelled superparamagnetic iron oxide nanoparticles in rat sentinel lymph nodes in vivo
(
- Contribution to journal › Article
- 2016
-
Mark
Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2
(
- Contribution to journal › Article
-
Mark
Effects of high photon fluence rate from therapeutic radionuclides on preclinical and clinical PET systems
2016) IEEE Nuclear Science Symposium and Medical Imaging Conference, NSS/MIC 2014 In 2014 IEEE Nuclear Science Symposium and Medical Imaging Conference, NSS/MIC 2014(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
- 2015
-
Mark
Human Anti-Oxidation Protein A1M-A Potential Kidney Protection Agent in Peptide Receptor Radionuclide Therapy.
(
- Contribution to journal › Scientific review
-
Mark
Biodistribution and pharmacokinetics of recombinant α1-microglobulin and its potential use in radioprotection of kidneys.
(
- Contribution to journal › Article
-
Mark
Intratherapeutic Biokinetic Measurements, Dosimetry Parameters Estimate, and Monitoring Treatment Efficacy using Cerenkov Luminescence Imaging in Preclinical Radionuclide Therapy.
(
- Contribution to journal › Article
-
Mark
Radiolabeled antibodies in prostate cancer: A case study showing the effect of host immunity on antibody bio-distribution.
(
- Contribution to journal › Article